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Abstract 
Background: In most individuals, obesity and insulin resistance coexist. However, some individuals have excessive 
adipose tissue mass but remain insulin sensitive. Moreover, lean individuals can develop acute inflammation-induced 
insulin resistance, even without excess adipose tissue mass.
Objective: Our aim was to compare inflammatory markers in overweight, insulin-sensitive and lean, insulin-resistant 
healthy subjects.
Methods: A cross-sectional study with 1098 participants (CAMELIA project) was conducted in family doctor primary 
care program at Niteroi, RJ, Brazil. In the present substudy, we have selected non-obese healthy subjects (n = 203). 
Insulin resistance was defined by a homeostatic model assessment (HOMA-IR) >2.6, and overweight subject BMIs 
were 25< BMI <30 kg/m2. Associations were estimated through binary logistic regression with generalized estimation 
equation models.
Results: We compared overweight, insulin-sensitive healthy individuals (n = 74) with a mean age of 39.2 ± 1.3 and 
lean, insulin-resistant healthy individuals (n = 18) with a mean age of 31.9 ± 3.6. C-reactive protein levels were posi-
tively correlated with body mass index in the lean, insulin-resistant group. In the multiple regression model, a positive 
association was observed with MCP-1 and IL-6 expression after adjustment for age, waist circumference, glycated 
hemoglobin, resistin, adiponectin, C-reactive protein and PAI-1 levels.
Conclusion: Our findings suggest that a lean, insulin-resistant subject may have higher pro-inflammatory marker 
levels (MCP-1, IL-6 and resistin) than an overweight, insulin-sensitive subject. This suggest an early risk phenotype that 
should further be investigated for possible prognostic implications.
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Background
During the last century, epidemiologic studies have sug-
gested a possible relationship between inflammation and 
insulin resistance [1]. More recently, this evidence has 
become robust and suggests that obesity and inflamma-
tion are the main components of insulin resistance [2, 3]. 
The adipose tissue is directly involved in the inflamma-
tory response and produces several cytokines, such as 
adiponectin, resistin, interleukin-6 (IL-6), plasminogen 
activator inhibitor-1 (PAI-1) and monocyte chemotactic 
protein-1 (MCP-1). Excess adipose tissue also promotes 
inflammation, which is accompanied by monocyte and 
B and T lymphocyte infiltration [4]. Chronic inflam-
matory state in obesity is maintained by interactions 
between leptin and inflammation, where an increase on 
pro-inflammatory cytokines leads to leptin release. In 
most individuals, insulin resistance and obesity coexist. 
However, some subjects with excessive body fat have bet-
ter insulin sensitivity than expected for their adiposity 
[5]. Conversely, lean subjects can develop inflammation-
associated insulin resistance [6].
Despite the importance of inflammation, studies com-
paring the individual impacts of obesity and insulin 
resistance on inflammatory activation are not found in 
the literature. This comparison will expand our knowl-
edge concerning the complex dynamics of inflammation, 
adiposity and insulin resistance.
Our aim was to describe and compare inflammatory 
markers in overweight, insulin-sensitive and lean, insu-
lin-resistant subjects, assisted by a family doctors pri-
mary care program.
Methods
The Cardio-neuro-Metabolic-renal Familial (CAMELIA) 
project is a transverse observational study with 1098 
participants in which cardiologists, neurologists, psy-
chiatrists, endocrinologists, nephrologists, general doc-
tors, nutritionists, nurses and students participated; this 
project aimed to study cardiovascular risk factors and 
related issues, such as familial aggregation. This project 
was conducted between July 2006 and December 2007 in 
13 modules of the Family Doctors Program of Niteroi, RJ, 
Brazil, which was selected in an attempt to include all of 
the politico-administrative regions of the city. Data col-
lection (demographic, anthropometric, clinical, psycho-
logical, nutritional, and blood and urine samples) was 
performed during project visits to each regional family 
doctor clinic (to assess more detailed CAMELIA pro-
ject information, see Ref. [7]). The insulin, PAI-1, MCP-
1, resistin, adiponectin and IL-6 were analyzed on a 
Luminex®. C reactive protein (CRP) was analyzed using 
an ELISA commercial kit. The sample criteria selec-
tion for this substudy aimed to include healthy subjects, 
without any comorbidity. We included those who were 
older than 18  years; did not have any cardiovascular 
diseases (myocardial infarction, heart failure, cerebro-
vascular accident); were not under medication for hyper-
tension, diabetes, or hyperlipidemia; had a BMI (body 
mass index)  <30  kg/m2; and had no previous diagnosis 
of diabetes. Overweight was defined as having a BMI 
25<  BMI  <30  kg/m2 [8]. Insulin resistance was defined 
as a homeostatic model assessment (HOMA-IR)  >2.6 
[9–11]. From among these subjects, we have selected 
203 subjects and separated into 4 groups: (a) normal 
BMI subjects (<25  kg/m2) with preserved insulin sensi-
tivity; (b) normal BMI subjects (<25 kg/m2) with insulin 
resistance (c) overweight subjects with preserved insulin 
sensitivity; (d) overweight subjects with insulin resist-
ance. After analysis, we finally selected 92 non-obese 
healthy subjects and separated them into 2 groups: (I) 
normal BMI subjects (<25 kg/m2) with insulin resistance 
(n = 18), OW(−)IR(+); (II) overweight subjects with pre-
served insulin sensitivity (n = 74), OW(+)IR(−).
Parametric variables were analyzed with Student’s t 
test, and non-parametric variables were analyzed with 
the Spearman test correlation. Univariate parametric 
(Student’s T) and non-parametric (Mann–Whitney) tests 
were used to investigate potential differences between 
the groups. For generalized estimated equations (GEE), 
binary logistic regressions were performed with variables 
that reached p values <0.150 on parametric and non-par-
ametric tests and included cytokines and variables related 
to adiposity and glucose metabolism. Statistical analysis 
was performed using SPSS Statistics 17® software. The 
data were statistically significant at p < 0.05. The CAME-
LIA study protocol was approved by the Federal Flumin-
ense University Ethics Committee (UFF/Huap#220/05), 
and all of the patients signed written consent forms.
Results
In the OW(+)IR(−) group, the mean age was 39.2 ± 1.3, 
and 49 were female (66.2  %), and in the OW(−)IR(+) 
group, the mean age was 31.9 ± 3.6, and 12 were female 
(66.7  %). Demographic, anthropometric and biochemical 
variables are listed in Table 1. The variables that exhibited 
differences between the groups were age, skin color and 
high-risk abdominal circumference. The non-parametric 
analysis is shown in Table  2. Lean, insulin-resistant sub-
jects [OW(−)IR(+) group] had significantly higher MCP-1 
and IL-6 levels and a lower prevalence of high-risk waist 
circumference, compared with overweight non-insulin 
resistant group. Multivariate analysis by GEE showed that 
the presence of insulin resistance was associated with 
increased MCP-1 (OR =  1.005, p =  0.007) and IL-6 lev-
els (OR = 1.263, p = 0.026) and with reduced adiponec-
tin levels (OR  =  0.893, p  =  0.033) after adjustment for 
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skin color, age, waist circumference and glycated hemo-
globin (Table 3, model 1). In model 2 (Table 3), all of the 
studied cytokines were included, skin color and glycated 
hemoglobin were excluded. Model 2 (Table 3) shows that 
presence of insulin resistance was positively associated 
with MCP-1 (OR  =  1.005, p  =  0.024) and IL-6 levels; 
and, negatively associated with CRP levels (OR =  0.989, 
p  =  0.049). In model 3 (Table  3), glycated hemoglobin 
was included, waist circumference was excluded. Model 
3 (Table 3) shows that presence of insulin resistance was 
positively associated with resistin (OR = 1.017, p = 0.001), 
IL-6 (OR  =  1.393, p  =  0.002) and glycated hemoglobin 
(OR  =  3.332, p  =  0.036) and negatively associated with 
age (OR = 0.921, p = 0.024) and PAI-1 levels (OR = 0.981, 
p  =  0.017). Waist circumference was included in model 
4 (Table  3), in which it was observed that presence of 
insulin resistance was positively associated with MCP-1 
(OR  =  1.006, p  =  0.024) and IL6 levels (OR  =  1.361, 
p = 0.016), which were stronger than in the previous mod-
els 1 and 2. As shown in Figs. 1, 2, CRP levels presented a 
positive correlation with BMI (r = 0.695, p = 0.001) and 
waist circumference (r = 0.628, p = 0.005) in OW(−)IR(+) 
group. Conversely, in OW(+)IR(−) group, BMI presented 
negative correlation with IL-6 (r = −0.245, p = 0.036) and 
MCP-1 levels (r  =  −0.269, p  =  0.020), as seen, respec-
tively, in Figs. 3, 4.
Discussion
In the present study, lean, insulin-resistant subjects pre-
sented a more inflammatory profile than overweight, 
insulin-sensitive subjects. Several studies have demon-
strated that obesity promotes a chronic inflammatory 
state that is associated with inflammatory macrophage 
infiltration and accumulation in adipose tissue and that 
contributes to the development of insulin resistance and 
diabetes [12–15]. However, obesity per se is not a pre-
condition for the development of insulin resistance but, 
rather, the degree of adipose tissue inflammation [4].
The local action of cytokines such as TNF-a on adipo-
cytes was one of the first pieces of evidence suggesting 
a possible link between insulin resistance and patho-
genic inflammatory processes [16]. Although adiposity is 
closely related to inflammation, our findings suggest that 
lean, insulin-resistant individuals could present higher 
levels of inflammatory biomarker even without exces-
sive adipose tissue, compared with an overweight sub-
ject without insulin resistance. When endotoxemia was 
induced in healthy subjects, the acute inflammation was 
capable of modulating the signaling and inflammatory 
pathways in adipose tissue, thus causing insulin resist-
ance, without an increase on adiposity [6]. Resistin is a 
pro-inflammatory cytokine that can promote systemic 
insulin resistance when injected in mice [1, 17]. Although 
this effect is supported by strong animal study evidences, 
the human-related data are less consistent [18, 19]. In 
our study, multivariate analysis indicated that lean, 
insulin-resistant subjects presented higher resistin levels 
(OR  =  1.017, p  =  0.001) compared with OW(+)IR(−) 
subjects after adjustment for age, IL-6, MCP-1, CRP, adi-
ponectin and glycated hemoglobin levels (Table 3, model 
3). The same association remained strong in models 
adjusted for waist circumference (Table  3, models 2, 4). 
Additionally, resistin-deficient ob/ob mice, even with an 
increased body adiposity, have normal glucose tolerance 
Table 1 Demographic, anthropometric and  laboratorial 
data, according to presence of overweight (n = 74) or insu-
lin resistance (n = 18)
a  Normal HDL-C: ≥40 mg/dL for men or ≥50 mg/dL for women
b  Elevated Uric Acid: >6.8 mg/dL for men and >6 mg/dL for women
Variables wtih p values <0.150 were selected for logistic binary modeling
Statistical significance was considered as p < 0.05 (in italics)
OW(+)IR(−) OW(−)IR(+) p value
Gender 1,000
 Female 49 (66.2) 12 (66.7)
 Male 25 (33.8) 6 (36.8)
Age <0.001
<20 years 1 (1.4) 7 (38.9)
 20–29 17 (23.0) 4 (22.2)
 30–39 19 (25.7) 1 (5.6)
 40–49 28 (37.8) 3 (16.7)
 50–59 7 (9.5) 3 (16.7)
 60 ou+ 2 (2.7) 0 (5.3)
Skin color 0.016
 Black or mulatto 59 (78.7) 9 (50.0)
 White 15 (20.3) 9 (50.0)
Total cholesterol 0.276
 <200 mg/dL 46 (62.2) 14 (77.8)
 ≥200 mg/dL 28 (37.8) 4 (22.2)
HDL-Ca 0.603
 Normal 39 (52.7) 11 (61.1)
 Elevated 35 (47.3) 7 (38.9)
Triglycerides 0.404
 <150 mg/dL 67 (90.5) 15 (83.3)
 ≥150 mg/dL 7 (9.5) 3 (16.7)
Uric acidb 0.251
 Normal 71 (95.9) 15 (88.9)
 Elevated 3 (4.1) 2 (11.1)
Blood pressure 0. 529
 Normal 59 (79.7) 13 (72.2)
 Hypertension 15 (20.3) 5 (27.8)
Abdominal circumference 0.027
 Normal 45 (60.8) 16 (88.9)
 High-risk 29 (39.2) 2 (11.1)
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and preserved insulin sensitivity [20]. This suggests that 
resistin is a key player on the induction of insulin resist-
ance and it is closely related to it.
MCP-1 is a cytokine that activates cells from the mono-
cytic lineage, enhances CD11b/CD18 expression, and 
increases pro-inflammatory cytokines in human endotox-
emia model [21, 22]. A recent study on transgenic mice 
demonstrated that MCP-1 overexpression in visceral 
adipose tissue resulted in elevated plasma MCP-1 levels 
and robust inflammatory macrophage recruitment that 
Table 2 Mann-Whitney Test for non-parametric variables, according to presence of overweight (n = 74) or insulin resist-
ance (n = 18)
a Macrophage Chemoattractant Protein-1
b  Interleukin-6
c  Plasminogen activator inhibitor-1
Variables wtih p values <0.150 were selected for logistic binary modeling
Statistical significance was considered as p < 0.05  (in italics)
OW(+)IR(−) (mean-rank) OW(−)IR(+) (mean-rank) P value
Age 49.88 32.61 0.014
Circumference
Waist 53.05 19.58 <0.001
Abdominal 52.72 20.94 <0.001
Glycated hemoglobin 43.86 54.67 0.120
Cytokines
 C reactive protein 47.80 41.17 0.345
 MCP-1a 43.34 59.50 0.021
 IL-6b 43.42 59.17 0.025
 Resistin 44.95 52.89 0.258
 Adiponectin 43.95 56.97 0.063
 PAI-1c 46.41 46.86 0.949
Table 3 Adjusted logistic regression models , according to  presence of  insulin resistance [OW(−)IR(+)] or absence 
[OW(+)IR(−)]
Binary logistic model adjusted by GEE-In model 1, the variables included were that reached p value <0.150 on parametric and non-parametric tests (Tables 1 and 2). 
In model 2, all cytokines and a variable related to overweight were included. In model 3, all cytokines and a variable related to glucose metabolic imbalance were 
included, and waist circumference was excluded. In model 4, all cytokines, a variable related to glucose metabolic imbalance and a variable related to overweight 
were included
a  Macrophage Chemoattractant Protein-1
b  Interleukin-6
c  Plasminogen activator inhibitor-1
* p value <0.050
** p value <0.010
Statistical significance was considered as p < 0.05  (in italics)
Model 1 Model 2 Model 3 Model 4
OR (95 %) OR (95 %) OR (95 %) OR (95 %)
Age 1.083 (0.925–1.268) 1.064 (0.940–1.205) 0.921 (0.858–0.989)* 1.049 (0.898–1.225)
MCP-1a 1.005 (1.001–1.008)** 1.005 (1.001–1.010)* 1.003 (0.999–1.006) 1.006 (1.001–1.011)*
C reactive protein – 0.989 (0.979–1.000)* 0.984 (0.966–1.003) 0.992 (0.976–1.008)
IL-6b 1.263 (1.029–1.551)* 1.361 (1.060–1.747)* 1.393 (1.133–1.713)** 1.390 (1.106–1.746)**
Resistin – 1.016 (1.000–1.033) 1.017 (1.010–1.025)** 1.015 (0.997–1.034)
PAI-1c – 0.993 (0.976–1.009) 0.981 (0.966–0.997)* 0.985 (0.961–1.011)
Adiponectin 0.893 (0.804–0.991)* 0.868 (0.727–1.037) 1.012 (0.978–1.048) 0.919 (0.741–1.139)
Waist circumf 0.653 (0.471–0.905)* 0.676 (0.514–0.888)** – 0.693 (0.532–0.903)**
Glycated Hb 1.978 (0.813–4.814) – 3.332 (1.079–10.293)* 2.575 (0.481–13.801)
White 0.457 (0.089–2.274) – – –
Mulatto or black 1 – – –
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caused systemic insulin resistance [23]. Additionally, adi-
pose tissue macrophages contribute significantly to the 
elevation of cytokine levels, such as TNF-a and IL-6 [13, 
24]. IL-6 was one of the first pro-inflammatory cytokines 
to be implicated in insulin resistance pathogenesis and as 
a cardiovascular risk factor. Diabetic patients present high 
levels of serum IL-6 [25]. In our study, lean, insulin-resist-
ant subjects had higher IL-6 (OR = 1.263, p = 0.026) and 
MCP-1 levels (OR = 1.005, p = 0.007) than OW(+)IR(−) 
patients (Table  3, model 1). After adjustment for age, 
waist circumference, resistin, CRP, PAI-1, adiponectin 
and glycated hemoglobin levels, the association of having 
insulin resistance and higher levels of IL-6 (OR = 1.390, 
p = 0.005) and MCP-1 (OR = 1.006, p = 0.026) became 
stronger (Table 3, model 4). Conversely, in an interesting 
Japanese study, increased visceral fat mass, as measured 
by tomography, was an independent predictor for the 
elevation of CRP levels in individuals with mild obesity or 
reduced glucose tolerance [26]. This is Japanese study also 
showed, with multiple linear regression, that visceral fat 
exhibited a higher correlation to CRP levels [26]. Similarly, 
in our present study, CRP levels had presented a strong 
Fig. 1 Correlation between C reactive protein and body mass index, according to the presence of overweight (n = 74) or insulin resistance (n = 18)
Fig. 2 Correlation between C reactive protein and waist circumference, according to presence of overweight (n = 74) or insulin resistance (n = 18)
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correlation with BMI (r  =  0.695, p  =  0.001) and waist 
circumference (r = 0.628, p = 0.005) in the lean, insulin 
resistant group, as seen in Figs. 1, 2. However, these corre-
lations were not found in the OW(+)IR(−) group. Addi-
tionally, the OW(+)IR(−) subjects had higher CRP levels 
according to logistic regression (OR = 0.989, p = 0.049) 
compared with the OW(−)IR(+) group, independent of 
age, waist circumference, IL-6, MCP-1, resistin, PAI-1 and 
adiponectin levels (Table 3, model 2).
The association between abdominal obesity and 
increased circulating PAI-1 levels was first described 
more than 20  years ago [27, 28]. More recently, it has 
been proposed that adipose tissue directly contributes to 
increased PAI-1 levels in obesity [29, 30]. Several inter-
ventional studies have demonstrated that a significant 
reduction in PAI-1 levels occurs after obese people lose 
weight through diet [31, 32] or jejunoileal bypass sur-
gery [33]. Additionally, the reduced PAI-1 levels associ-
ated with losing weight is suggested to be related to the 
amount of weight lost and not to metabolic changes, 
such as variations on insulin or triglyceride levels [31, 
32]. In our study, multivariate regression demonstrated 
Fig. 3 Correlation between interleukin-6 and body mass index, according to presence of overweight (n = 74) or insulin resistance (n = 18)
Fig. 4 Correlation between MCP-1 and body mass index, according to presence of overweight (n = 74) or insulin resistance (n = 18)
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that OW(+)IR(−) subjects had higher PAI-1 levels than 
the lean, insulin-resistant group (OR = 0.981, p = 0.017), 
independent of age, cytokine levels and glycated hemo-
globin (Table  3, model 3). However, when the statisti-
cal models were adjusted for waist circumference, this 
association got weaker (Table 3, models 2, 4), which it is 
explained by the close relationship between PAI-1 and 
adiposity.
In contrast to other cytokines, adiponectin has anti-
inflammatory, anti-apoptotic, and pro-angiogenic effects 
and is capable of enhancing insulin sensitivity on tis-
sues [34, 35]. Reduced adiponectin levels are detected 
in diabetes, hypertension and coronary arterial disease, 
even when adjusted for BMI. Complementarily, insu-
lin resistance diminished when hypoadiponectinemia is 
normalized by treatment with recombinant adiponec-
tin in a type-2 diabetes animal model [36]. Interestingly, 
in a study of Pima Indians, who have high prevalence 
of type-2 diabetes, subjects with high adiponectin lev-
els were found to be less likely to develop diabetes than 
those with low concentrations, which suggests a protec-
tive effect [37]. In our study, the multivariate regression 
revealed that the OW(+)IR(−) group had higher adi-
ponectin levels compared with the OW(−)IR(+) group 
(OR  =  0.893, p  =  0.027), independent of age, waist 
circumference, skin color, IL-6, MCP-1, and glycated 
hemoglobin levels (Table  3, model 1). This finding is 
highly interesting because adiponectin levels are usually 
inversely related to BMI, waist circumference, body fat 
percentage and insulin resistance; however, in our study, 
adiponectin levels were higher in overweight subjects 
than in insulin-resistant subjects.
Obese or overweight but metabolically healthy indi-
viduals continue to represent a challenging phenotype. 
However, possible explanations reside in interpersonal 
differences in body fat distribution; life habits, such as 
physical activity; and metabolic dynamics of adipose 
tissue balance [38]. A recent study demonstrated that 
for the same degree of severe obesity, individuals with 
reduced adipose tissue inflammation exhibited an “inter-
mediate” clinical phenotype with arterial function simi-
lar to that of normal weight subjects [39]. This evidence 
suggests that the exclusively overweight subjects (with-
out insulin resistance) in our study represent a meta-
bolically healthy phenotype with reduced inflammatory 
activity (lower cytokine and higher adiponectin levels) 
despite excess adipose tissue. Additionally, OW(+)IR(−) 
subjects had an inverse correlation of waist circumfer-
ence with IL-6 levels (r = −0.245, p = 0.036). Cytokines 
that are closely related to adiposity (PAI-1 and CRP) 
were increased in the overweight group despite lower 
levels of the other cytokines (IL-6, MCP-1 and resistin) 
(Table 3).
The limitations of our study were its sample size and 
selection criteria; HOMA-IR was utilized to identify insulin 
resistance, although it is not the gold standard for diagno-
sis, and BMI, despite its prevalence, is not the most trusted 
index for estimating obesity. Although, BMI has a high and 
independent association with the risk of incidence of type 
II diabetes [40]. The impact of the latter is considered to be 
reduced by other adjusting factors, such as inflammatory 
markers, waist, abdominal and hip circumferences.
Conclusion
Our findings suggest that an individual with normal BMI 
and a HOMA index greater than 2.6 has a significantly 
higher probability of presenting elevated levels of pro-
inflammatory biomarkers (MCP-1, IL-6 and resistin) 
than an overweight subject with a HOMA index less than 
2.6. More studies are necessary to clarify and extend the 
understanding of this complex syndrome.
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